(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
In Antarctica, photos show a remote area teeming with life amid growing risks from climate change - 2Barry Manilow to have surgery for early-stage lung cancer and postpones January concerts
- 3Virtual reality opens doors for older people to build closer connections in real life
- 44K televisions for Extreme Film Watching Experience
- 5EU calls on Western Balkans to step up reforms for membership
- The face is familiar, the name might not be. The king of "Hey, it's that guy!' roles is ready to show you his next act.
- Australia Cracks Down on Gambling Ads as Prediction Markets Like Polymarket Remain Blocked
- Instructions to Guarantee Kids Foster Solid Dental Propensities
- The moon and sun figure big in the new year's lineup of cosmic wonders
- 2024 Ferrari Roma With Just One Owner & 3,300 Miles For Sale At $...
- Central African Republic's president sworn in for a third term after disputed election
- The Electric Toyota Hilux Is Finally here, But It's Not Cheap
- The Best 10 Innovation Developments of the Year
- Figure out how to Team up with Your Auto Crash Legal advisor for Best Outcomes
